Helsinn gains worldwide rights to Advancell's PhII skin injury drug
This article was originally published in Scrip
Executive Summary
Swiss pharma Helsinn and emerging Spanish biotech Advancell have signed a partnering agreement giving Helsinn worldwide development and commercialization rights to Advancell's ATH008, a topical product to treat skin injuries caused by chemotherapy.